

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Warfarin potassium

November 26, 2025

Therapeutic category

Anticoagulants

Non-proprietary name

Warfarin potassium

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision
<p>11. ADVERSE REACTIONS</p> <p>11.1 Clinically Significant Adverse Reactions</p> <p>Haemorrhage</p> <p>Intraorgan haemorrhage such as cerebral haemorrhage, mucosal haemorrhage, haemorrhage subcutaneous, etc. may occur. If the anticoagulant effect of this drug needs to be rapidly decreased, administration should be discontinued and administration of vitamin K preparation should be considered. If serious haemorrhage including cerebral haemorrhage occurs, appropriate measures such as intravenous injection of prothrombin complex or transfusion of fresh frozen plasma should be taken as necessary. When these measures are taken, sufficient attention should be paid to recurrence of thrombus.</p>	<p>11. ADVERSE REACTIONS</p> <p>11.1 Clinically Significant Adverse Reactions</p> <p>Haemorrhage</p> <p>Intraorgan haemorrhage such as cerebral haemorrhage and <u>splenic haemorrhage leading to splenic rupture</u>, mucosal haemorrhage, haemorrhage subcutaneous, etc. may occur. If the anticoagulant effect of this drug needs to be rapidly decreased, administration should be discontinued and administration of vitamin K preparation should be considered. If serious haemorrhage including cerebral haemorrhage occurs, appropriate measures such as intravenous injection of prothrombin complex or transfusion of fresh frozen plasma should be taken as necessary. When these measures are taken, sufficient attention should be paid to recurrence of thrombus.</p>